apricus wealth LLC Raises Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

apricus wealth LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 37.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 600 shares of the medical research company’s stock after acquiring an additional 163 shares during the period. apricus wealth LLC’s holdings in Thermo Fisher Scientific were worth $312,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC increased its position in Thermo Fisher Scientific by 18.1% during the second quarter. AQR Capital Management LLC now owns 98,152 shares of the medical research company’s stock valued at $54,278,000 after acquiring an additional 15,009 shares during the last quarter. Daymark Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 24.5% in the second quarter. Daymark Wealth Partners LLC now owns 619 shares of the medical research company’s stock worth $342,000 after purchasing an additional 122 shares during the last quarter. MBB Public Markets I LLC raised its holdings in shares of Thermo Fisher Scientific by 767.0% in the second quarter. MBB Public Markets I LLC now owns 29,278 shares of the medical research company’s stock worth $16,191,000 after buying an additional 25,901 shares during the period. Lummis Asset Management LP boosted its holdings in Thermo Fisher Scientific by 1.2% during the 2nd quarter. Lummis Asset Management LP now owns 3,030 shares of the medical research company’s stock valued at $1,676,000 after acquiring an additional 37 shares during the period. Finally, Lighthouse Investment Partners LLC increased its stake in Thermo Fisher Scientific by 91.3% in the second quarter. Lighthouse Investment Partners LLC now owns 10,892 shares of the medical research company’s stock worth $6,023,000 after purchasing an additional 5,199 shares during the period. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. TD Cowen raised their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Morgan Stanley decreased their price target on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Bernstein Bank raised their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Finally, Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $648.95.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,850 shares of Thermo Fisher Scientific stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $557.89, for a total value of $3,263,656.50. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,611,804.88. The trade was a 4.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders sold 44,850 shares of company stock valued at $24,666,097. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $575.21 on Friday. The firm has a market cap of $220.02 billion, a PE ratio of 36.06, a P/E/G ratio of 3.82 and a beta of 0.76. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The business has a 50-day moving average price of $532.36 and a 200 day moving average price of $569.05. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. During the same quarter in the prior year, the company earned $5.69 EPS. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a stock repurchase program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.